JonathanKolitzMD

PubMed

• 1 citations
  Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
  Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, Ayse S Yilmaz, Jessica Kohlschmidt, Karilyn T Larkin, James S Blachly, Christopher C Oakes, Jill Buss, Christopher J Wa...> ;Leukemia. 2024 Jan 1
• Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
  Bhavana Bhatnagar, Jessica Kohlschmidt, Shelley J Orwick, Daelynn R Buelow, Sydney Fobare, Christopher C Oakes, Jonathan E Kolitz, Geoff Uy, Wendy Stock, Bayard L Powe...> ;Blood Advances. 2023 Aug 22
• Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
  Bhavana Bhatnagar, Jessica Kohlschmidt, Shelley J Orwick, Daelynn R Buelow, Sydney Fobare, Christopher C Oakes, Jonathan E Kolitz, Geoff Uy, Wendy Stock, Bayard L Powe...> ;Blood Advances. 2023 Aug 22
• 14 citations
  Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
  Krzysztof Mrózek, Jessica Kohlschmidt, James S Blachly, Deedra Nicolet, Andrew J Carroll, Kellie J Archer, Alice S Mims, Karilyn T Larkin, Shelley Orwick, Christopher ...> ;Leukemia. 2023 Apr 1
• 10 citations
  High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.
  Karilyn T Larkin, Deedra Nicolet, Benjamin J Kelly, Krzysztof Mrózek, Stephanie LaHaye, Katherine E Miller, Saranga Wijeratne, Gregory Wheeler, Jessica Kohlschmidt, Ja...> ;Blood Advances. 2022 Oct 11
• 2 citations
  Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.
  Byeongho Jung, Gerardo Ferrer, Pui Yan Chiu, Rukhsana Aslam, Anita Ng, Florencia Palacios, Michael Wysota, Martina Cardillo, Jonathan E Kolitz, Steven L Allen, Jacquel...> ;JCI Insight. 2022 Jun 22
• 1 citations
  CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis.
  Xinmin Zhang, Cristina Ghiuzeli, Erin Jou, Peihong Hsu, Jonathan Kolitz, Judith P Brody> ;Leukemia Research Reports. 2022 Jan 1
• 2 citations
  Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia.
  Matthew Kaufman, Xiao-Jie Yan, Wentian Li, Emanuela M Ghia, Anton W Langerak, Laura Z Rassenti, Chrysoula Belessi, Neil E Kay, Frederic Davi, John C Byrd, Sarka Pospis...> ;Frontiers in Oncology. 2022 Jan 1
• 10 citations
  Molecular associations, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia (Alliance).
  Sydney Fobare, Jessica Kohlschmidt, Hatice Gulcin Ozer, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, Ramiro Garzon, James S. Blachly, Shelley Orwick, Andrew J. Car...> ;Blood Advances. 2021 Nov 30
• 6 citations
  Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.
  Matthew J Wieduwilt, Jun Yin, Meir Wetzler, Geoffrey L. Uy, Bayard L. Powell, Jonathan E. Kolitz, Michaela Liedtke, Wendy Stock, Jan H. Beumer, Ryan J. Mattison, Eliza...> ;Blood Advances. 2021 Nov 23
• 3 citations
  Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.
  Dimitrios Papaioannou, Hatice Gulcin Ozer, Deedra Nicolet, Amog P. Urs, Tobias Herold, Krzysztof Mrózek, Aarif M. N. Batcha, Klaus H. Metzeler, Ayse Selen Yilmaz, Stef...> ;Haematologica. 2021 Jul 15
• 14 citations
  Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).
  Alison Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Eisfeld, Eunice S. Wang, Sawye...> ;Blood Advances. 2021 Jul 13
• 7 citations
  Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement
  Marius Bill, Krzysztof Mrózek, Brian Giacopelli, Jessica Kohlschmidt, Deedra Nicolet, Dimitrios Papaioannou, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Bayard L. Powell,...> ;Journal of Hematology & Oncology. 2021 Jul 6
• 72 citations
  CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a ra...
  Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Dale L. B...> ;The Lancet. Haematology. 2021 Jul 1
• 7 citations
  A precision medicine classification for treatment of acute myeloid leukemia in older patients.
  Alice S. Mims, Jessica Kohlschmidt, Uma Borate, James S. Blachly, Shelley Orwick, Ann-Kathrin Eisfeld, Dimitrios Papaioannou, Deedra Nicolet, Krzysztof Mrόzek, Eytan M...> ;Journal of Hematology & Oncology. 2021 Jun 23
• 12 citations
  Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course
  Davide Bagnara, Catherine Tang, Jennifer R. Brown, Siddha Kasar, Stacey M. Fernandes, Monica Colombo, Stefano Vergani, Andrea Nicola Mazzarello, Fabio Ghiotto, Silvia ...> ;Frontiers in Oncology. 2021 May 25
• 22 citations
  Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.
  Gerardo Ferrer, Byeongho Jung, Pui Yan Chiu, Rukhsana Aslam, Florencia Palacios, Andrea Nicola Mazzarello, Stefano Vergani, Davide Bagnara, Shih-Shih Chen, Sophia Yanc...> ;Leukemia. 2021 May 2
• 2 citations
  Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations.
  Alice S. Mims, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Krzysztof Mrόzek, James S. Blachly, Shelley Orwick, Dimitrios Papaioannou, Deedra Nicolet, Deepa Sampath, Rich...> ;Leukemia. 2021 Apr 1
• 11 citations
  Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: Phase 3 post hoc analyses
  Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz, Geoffrey L. Uy, Donna E. Hogge, Scott R. Solomon, Matthew J. Wieduwilt, Robert J....> ;Blood Advances. 2021 Mar 23
• 6 citations
  A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice.
  Piers E.M. Patten, Gerardo Ferrer, Shih Shih Chen, Jonathan E. Kolitz, Kanti R. Rai, Steven L. Allen, Jacqueline C. Barrientos, Nikolaos Ioannou, Alan G. Ramsay, Nicho...> ;Frontiers in Immunology. 2021 Mar 9
• 15 citations
  Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia
  Christopher J. Walker, Krzysztof Mrózek, Hatice Gulcin Ozer, Deedra Nicolet, Jessica Kohlschmidt, Dimitrios Papaioannou, Luke K Genutis, Marius Bill, Bayard L. Powell,...> ;Blood Advances. 2021 Mar 9
• 35 citations
  Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia.
  Bhavana Bhatnagar, Jessica Kohlschmidt, Krzysztof Mrózek, Qiuhong Zhao, James L. Fisher, Deedra Nicolet, Christopher J. Walker, Alice S. Mims, Christopher C. Oakes, Br...> ;Cancer Discovery. 2021 Mar 1
• 19 citations
  Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target.
  Florencia Palacios, Xiao-Jie Yan, Gerardo Ferrer, Shih-Shih Chen, Stefano Vergani, Xuejing Yang, Jeffrey Gardner, Jaqueline C. Barrientos, Philip J Rock, Richard Burac...> ;Leukemia. 2021 Jan 27
• 44 citations
  Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A.
  Marius Bill, Krzysztof Mrózek, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Christopher J. Walker, Deedra Nicolet, Dimitrios Papaioannou, James S. Blachly, Shelley Orwick...> ;Proceedings of the National Academy of Sciences of the United States of America. 2020 Oct 20
• 60 citations
  Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
  Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Alice S. Mims, Deedra Nicolet, Christopher J. Walker, James S. Blachly, Andrew J. Carroll, Dimitrios Papaioannou, Jonathan E....> ;Leukemia. 2020 May 27
• Join now to see all

Journal Articles

• NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome  
  Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature
• Polyclonal expansion of activated T-Lymphocytes in patients treated with recombinant interleukin 2.  
  Kolitz, J.E., Welte, K. Holloway, K., Merluzzi, V.J., Bradley, E.C., Konrad, M., Engert, A., Polivca, A., Gabrilove, J.L., Groshen, S., Sykora, K.W., Miller, G.A., Fie..., J. Biol. Resp. Modifiers 1987; 6:412-429
• Defect of T. cell activation in common variable immunodeficiency is restored with phorbol myristate acetate.  
  Fiedler, W., Sykora, K.W., Welte, K., Kolitz, J., Cunningham-Rundles, C., Souza, L., Miller, G., Holloway, K., Mertelsmann, R, Clin. Immunol. Immunopathol. 1987; 44:206-218
• Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin.  
  Bialas, T., Kolitz, J., Levi, E,. Polivka, A., Oez, S., Miller, G., Welte, K, Cancer Res. 1988; 48:891-898
• Randomized study of 13-cis retinoic acid versus placebo in the myelodysplastic disorders.  
  Koeffler, H.P., Heitjan, D., Mertelsmann, R., Kolitz, J.E, Schulman, P., Itri, L., Gunter, P., Besa, E, Blood 1988; 71:703-708
• Phase I trial of intraperitoneal recombinant IL-2 in ovarian cancer.  
  Chapman, P., Kolitz, J.E., Hakes, T., Gabrilove, J., Welte, K., Engert, A., Merluzzi, V.J., Bradley, E., Oettgen, H., Mertelsmann, R, Invest. New Drugs 1988; 6: 179-188
• Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.  
  Kolitz, J.E., Wong, G.Y., Welte, K., Merluzzi, V.J., Engart, A., Bialas, T., Bradley, E.C., Konrad, M., Grecco, C., Oettgen, H.F., Mertelsmann, R, J. Biol. Resp. Modifiers 1988; 7: 457-472
• Anti-tumor efficacy of interleukin-2-activated killer cells in human neuroblastoma ex-vivo.  
  Atzpodien, J., Gulati, S.E., Kwon, J.H., Kushner, B.H., Shimazaki, C., Buhrer, C., Oz, S., Kolitz, J.E., Clarkson, B.D, Exper. Cell. Biol. 1988; 56:236-244
• Ewing’s sarcoma: ex-vivo sensitivity towards natural (NK) and lymphokine-activated (LAK) killing.  
  Atzpodien, J., Gulati, S., Buhrer, C., Oz, S., Khon, J.H., Kolitz, J.E., Clarkson, B, Oncology 1988; 45:437-443
• Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.  
  Shimazaki, C., Atzpodien, J., Wisniewski, D., Gulati, S.C., Kolitz, J.E., Fried, J., Clarkson, B.D, Acta. Haematol. 1988; 80:203-209
• A phase II study of human interleukin 2 in metastatic renal cell cancer and melanoma.  
  Lindemann, A., Herrman, F., Schmidt, R.E., Diehl, V., Kloke, O.,Gamm, H., Hayungs, J., Oster, W., Bohen, M., Kolitz, J.E., Hoffken, K., Mertelsmann, R, Cancer Immunol. Immunother. 1989; 28:275-281
• The pharmacokinetics of recombinant IL-2 in humans.  
  Konrad, M.W., Hemstract, G., Hersh, E., Mansell, P., Mertelsmann, R., Kolitz, J.E., Bradley, E.C, Cancer Res. 1990; 50:2009-2017
• Treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in blast crisis with high dose cytosine arabinoside (HDARAC).  
  Kempin, S., Arlin, Z., Berman, E., Gee, T., Mertelsmann, R., Andreeff, M., Kolitz, J., Jhanwar, S., Myers, J., Clarkson, B, Leukemia & Lymphoma 1991; 4:11-116
• Results of a ranodomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute no...  
  Berman, E., Heller, G., Santorsa, J., McKenzie, S., Gee, T.,Kempin, S., Gulati, S., Andreeff, M., Kolitz, J., Gabrilove, J., Reich, L., Mayer, K., Keefe, D., Trainor, ..., Blood 1991; 77:1666-1674
• Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy in relapsed and refractory lymphomas.  
  Crown, J.P., Gulati, S.C., Straus, D.J., Kolitz, J., Heelan, R., O’Brien, J., Straus, D.J., M., Lee, B.J., Portlock, C., Bertino, J, Invest. New Drugs 1991; 9:185-186
• Study of leukemia a of large granular lymphocytes using modern modalities.  
  Sun, T., Schulman, P., Kolitz, J.E., Brody, J., Koduru, P., Muuse, W., Broome, J, Amer. J. Hematol. 1992; 40:135-145
• Phase I evaluation of a water soluble etoposide prodrug,etoposide phosphate given as a 5-minute infusion on days 1, 3, 5 in patients with solid tumors.  
  Budman, D.R., Igwemezie, L.N.,Kaul, S., Behr, J., Lichtman, S., Schulman, P., Vinciguerra, V., Allen, S.L., Kolitz, J., Hock,K., O’Neill, K., Schacter, L., Barbhaiya R.H, J. Clin. Oncol. 1994; 12:1902-1909
• Peripheral T cell lymphoma in a patient with sinus histiocytosis and massive lymphadenopathy: molecular and cytogenetic studies.  
  Koduru, P., Susin, M., Kolitz, J.E., Brody, J., Amorosi, E., Budman, D, Amer. J. Hematol. 1995; 48:192-200
• Clinical and morphologic features of cases of trisomy 13 in acute non- lymphocytic leukemia.  
  Soni, M., Brody, J.,Allen, S., Schulman, P., Kolitz, J., Rai, K., Broome, J.D., Koduru, P.R.K, Leukemia 1996; 10:619-623
• Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells.  
  Fais, F., Sellars, B., Yan, X-J., Dono, M., Allen, S.L., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Schuster, M., Vinciguerra, V.P., Rai, K., S..., J. Clin. Invest. 1996; 98:1659-1666
• Granulocyte-colony stimulating factor (FilgrastimR) accelerates granulocyte and platelet recovery following intensive postremission chemotherapy for acute myeloid leuk...  
  Moore, J.O., Dodge, R.K., Amrein, P.C., Kolitz, J., Lee, E.J., Powell, B., Godfrey, S., Robert, F., Schiffer, C.A, Blood 1997; 89:780-788
• Clonal expansion within the CD4+CD57+ and CD8+CD57+ T-cell subsets in chronic lymphocytic leukemia.  
  Serrano, D., Monteiro, J., Allen, S.L., Kolitz, J., Schulman, P., Lichtman, S.M., Buchbinder, A., Vinciguerra, V., Chiorazzi, N., Gregersen, P.K, J Immunology 1997; 158:1492-1499
• Correlation between mutation in p53, p53 expression, cytogenetics, histologic type and duration of survival in patients with B-cell Non-Hodgkin’s Lymphoma.  
  Koduru, P.R.K., Raju, K., Vadmal, V., Menezes, G., Susin, M., Kolitz, J., Broome, J.D, Blood 1997; 90:4078-4091
• Acquired factor VIII inhibitors—successful treatment with an oral outpatient regimen.  
  Bayer, R.L., Lichtman, S.M., Allen, S.L., Budman, D.R., Buchbinder, A., Fetten, J., Kolitz, J., Loscalzo, J, Am J Hematol 1999; 60:70-71
• Malignant hemangioendothelioma presenting as multifocal intraskeletal lesions during pregnancy.  
  Ilasi, J.A., Smilari, T.F., Kolitz, J., Zanzi, I., Hajdu, S.I, J Reprod Med 1999; 44:49-52
• Join now to see all

Books/Book Chapters

• Development, Testing, and Use of Biologically Active Substances in Cancer Therapy. 
  Chapter: Treatment of Cancer with Interleukin 2 
  Mertelsmann, R., Welte, K., Sykora, K.W., Kolitz, J., Holloway, K., Fiedler, W., Miller, G., Merluzzi, V., Venuta, S., Engert, A., Stein, C., Polivka, A., Levi, EEditors: Schuff-Werner P., Pfizenmaier, K.Zuckschwerdt Verlag, Munich
• Cellular and Molecular Biology of Lymphokines. 
  Chapter: The role of interleukin 2 in human immunodeficiency states 
  Page 755 - 789Welte, K., Kolitz, J.E., Merluzzi, V.J., Flomenberg, N., Engert, A., Miller, G.A.,Holloway, K., Sykora, K.W., Venuta, S., Bradley, E., O’Reilly, R.J. Oettgen, H.F., Me...Editors: Sorg, C. and Schimpl, A.Academic Press, New York
• Modern Trends in Human Leukemia, Vol. VII. 
  Chapter: Cytokines with possible clinical utility 
  Page 97 - 102Mertelsmann R., Kolitz, J., Welte, K., Herrmann, FEditors: Neth, R., Gallo, R.C.
• Interleukin 2 and Killer Cells in Cancer. 
  Chapter: Synergism between cyclophosphamide and interleukin-2 
  Page 125 - 132Mertelsmann, R., Lindemann, A., Kolitz, J., Herrmann, FEditors: Lotzova, E. and Herberman, R.B.CRC Press
• Update on clinical trials of chemotherapy and bone marrow transplantation in acute myelogenous leukemia at Memorial Sloan-Kettering Cancer Center (MSKCC) 1966 to 1989. 
  Page 239 - 272Clarkson, B., Berman, E., Little, C., Andreeff, M., Kempin, S., Kolitz, J., Gabrilove, J., Cunningham, I., Castro-Malaspina, H., Gulati, S., O’Reilly, R., Gee, TEditors: Gale, R.P.Wiley-Liss, Inc, New York
• Conn’s Current Therapy 2000. 
  Chapter: Chronic Leukemias 
  Page 425 - 432Kolitz, J.E., Lichtman, S.MW.B. Saunders and Co
• Cancer in the Elderly. 
  Chapter: Leukemias, Lymphomas, Myelomas 
  Page 361 - 418Lichtman, S.M., Kolitz, JEditors: Hunter, C.P., Johnson, K.A., Muss, H.Marcel Dekker, Inc, New York
• Oncology: An evidence-based approach. 
  Chapter: Acute Myeloid Leukemia and the Myelodysplastic Syndromes 
  Kolitz, J.EEditors: Chang, A.E., Ganz, P.A., Hayes, D.F., Kinsella, T., Pass, H.I., Schiller, J.H., Stone, R.M., Streche.Springer
• Cancer in the Elderly. 
  Chapter: Multiple myeloma 
  Kolitz, J.E., Mazj, S., Lichtman, S.MEditors: Hunter, C.P., Johnson, K.A., Muss, H.Marcel Dekker, Inc, New York
• The Acute Leukemias In: Conn’s Current Therapy 2008. 
  Kolitz, J.EW.B. Saunders and Co
• Join now to see all

Abstracts/Posters

• CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By BrutonÍs Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrut...
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patient...
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leuke...
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia ...
  Moore, J.O., Seiter, K., Kolitz, J.E., Stock, W., Yu, R., Ffrankel, S.R, Blood 2004, 104:247a
• A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leuke...
  Stone, R.M., Moser, B., Schulman, P., Barrier, R.C., Kolitz, J.E., Allen, S.L., Stock, W., Galinsky, I.A., Khoury, H., Larson, R.A, Blood 2004, 104:249a
• t(8;21) Acute Myeloid Leukemia (AML) Differs from inv(16) AML in Pretreatment Characteristics, Outcome and Prognostic Factors Predicting Outcome: A Cancer and Leukemia...
  Marcucci, G., Mrózek, K., Ruppert, A.S., Maharry, K., Kolitz, J.E., Mayer, R.J., Pettenati, M.J., Powell, B.L., Edwards, C.G., Sterling, L.J., Vardiman, J.W., Schiffer..., Blood 2004, 104:556a
• Pre-Treatment Cytogenetics Predict Complete Remission and Long-Term Outcome in Patients (Pts) =60 Years with Acute Myeloid Leukemia (AML): Results from Cancer and Leuk...
  Farag, S.S., Archer, K.J., Mrózek, K., Vardiman, J.W.,Carroll, A.J., Pettenati, M.J., Powell, B.L., Moore, J.O., Kolitz, J.E., Baer, M.R., Bigner, S.H., Koduru, P.R., ..., Blood 2004, 104:164a
• In B-CLL, time to first treatment is de;pendent on the IgVH gene mutations and expression of CD38 on leukemic cells.
  Wasil, T., Rai, K.R., Albesiano, E., Damle, R.N., Allen, S.L., Kolitz, J., Chiorazzi, N, Proc. Amer. Soc. Clin. Oncol. 2005, 23:573s
• Phase I study of amonafide + cytosine arabinoside (AraC) in patients with poor risk acute myeloid leukemia.
  Allen, S.L., Kolitz, J.E., Lundberg, A., Champagne, M., Devost, S., Rubon, R., Drouin, M., Boss, M.A., Grieshaber, C.K., Budman, D.R, Proc. Amer. Soc. Clin. Oncol. 2005, 23:585s
• A randomized comparison of untreated acute myeloid leukemia patients < 60 years using p-glycoprotein modulation with Valspodar (PSC833): preliminary results of Cancer ...
  Kolitz, J.E., George, S.L., Marcucci, G., Vij, R., Powell, B.L., Allen, S.L., DeAngelo, D.J., Shea, T., Stock, W., Hars, V., Hoke, E., Vardiman, J.W., Bloomfield, C.D...., Blood 2005, 106:122a
• Treatment failure is strongly predicted by p-glycoprotein function but not by multidrug resistance protein (MRP-1), breast cancer resistance protein (BCRP) or lung res...
  Baer, M.R., Cuviello, N.W., Shoemaker, J.S., Barrier, R.C., Caligiuri, M.A., Kolitz, J.E., Powell, B.L., Larson, R.A., Bloomfield, C.D, Blood 2005, 106:661a
• Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia (ALL): final results from Cancer and Leukemia Group B study 19802.
  Stock, W., Johnson, J., Yu, D., Bennett, D, Sher, D., Stone, R.M., Kolitz, J.E., Powell, B.L., Wetzler, M., Vardiman, J.W., Bloomfield, C.D., Larson, R.A, Blood 2005, 106:521a
• Effective asparagines depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia (ALL) – Cancer and Leukemia Group B stud...
  Wetzler, M., Sanford, B.L., Owzar, K., Kurtzberg, J., DeOliveira, D., Frankel, S.R., Powell, B.L., Kolitz, J.E., Bloomfield, C.D., Larson, R.A, Blood 2005, 106:519a
• Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Canc...
  Marcucci, G., Radmacher, M.D., Ruppert, A.S., Mrozek, K., Kolitz, J.E., Whitman, S.P., Edwards, C.G., Vardiman, J.W., Caligiuri, M.A., Carroll, A.J., Larson, R.A., Blo..., Blood 2005, 106:223a
• Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB).
  Marcucci,G., Baldus, C.D., Ruppert, A.S., Radmacher, M.D., Mrózek, K., Whitman, S.P., Kolitz, J.E., Edwards, C.G., Vardiman, J.W., Powell, B.L., Baer, M.R., Moore, J.O..., Blood 2005, 106:101a
• Clinical and cytogenetic responses to amonafide in secondary acute myeloid leukemia (AML).
  Allen, S.L., Kolitz, J.E., Lundberg, A.S., Capizzi, R.L., Budman, D.R, Proc. Amer. Soc. Clin. Oncol., 2006, 24:357s
• Remarkable Differences in Cellular Activation State and Migratory and Proliferative Potential among Clonal Cells Derived from Different Tissues of Chronic Lymphocytic ...
  Damle, R.N., Banapour, T., Temburni, S., Wasil, T., Kolitz, J.E. Allen, S.L., Sherry,B., Rai, K.R., Chiorazzi, N, Blood, 2006; 108: 2817
• FLT3 D385/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN-AML) without FLT3 internal ...
  Whitman, S.P., Ruppert, A.S., Radmacher, M.D., Mrozek, K., Paschka, P., Kolitz, J.E., Larson, R.A., Caligiuri, M.A., Marcucci, G., Bloomfield, C.D, Proc. Amer. Soc. Clin. Oncol. 2007, 25: abstract 20532
• A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute mye...
  Marcucci, G., Moser, B., Blum, W., Stock, W., Wetzler, M., Kolitz, J.E., Thakuri, M., Carter, T., Stuart, R.K., Larson, R.A, Proc. Amer. Soc. Clin. Oncol., 2007, 25: abstract 7012
• High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal acute myeloid...
  Langer, C., Ruppert, A.S., Radmacher, M.D., Whitman, S.P., Paschka, P., Baldus, C.D., Mrózek, K., Kolitz, J.E., Marcucci, G., Bloomfield, C.D, Proc. Amer. Soc. Clin. Oncol., 2007, 25: abstract 7013
• MicroRNA (miR) expression signatures in molecular subsets of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study.
  Radmacher, M.D., Marcucci, G., Paschka, P., Vukosavljevic, T., Whitman, S.P., Ruppert, A.S., K. Mrózek, K., Kolitz, J.E., Larson, R.A., Bloomfield, C.D, Proc. Amer. Soc. Clin. Oncol., 2007, 25: abstract 7013
• Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) vs. observation in patients < 60 years old with acute myeloid leukemia in first complete remiss...
  Kolitz, J.E., Hars, V., DeAngelo, D.J.,Allen, S.L., Shea, T.C., Vij, R., Hoke, E., Bloomgfield, C.D., Caligiuri, M.A., George, S.L., Larson, R.A, Blood 2007; 110:53a
• Join now to see all

Lectures

• Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Musashi 2 Is Overexpressed in Poor Outcome CLL Patients and Their Proliferative Fraction and Silencing This Gene Induces Apoptosis and Increases Cell Adhesion and Move... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genome-Wide Association Study (GWAS) Identifies a Significant Acute Myeloid Leukemia (AML) Susceptibility Locus Near BICRA 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid L... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutations in Genes Associated with Familial Predisposition to Myeloid Neoplasms: Their Frequency and Associations with Pretreatment Characteristics in Adult Patients (... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all

Other

• Interleukin 2 - Basic and Clinical Studies. 
  Kolitz, J.E., Mertelsmann, R., Welte, K, Cancer Bulletin (M.D. Anderson Hospital) 1987; 39:13-18
• Acute leukemia in adults. 
  Kolitz, J.E, Dis. Month 2008: 54:226-241